Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiya Horimoto

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
The American Journal of Pathology|July 19, 2011
ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancerYoshiya Horimoto, Johan Hartman, Julie Millour, et al.
Clinical Breast Cancer|December 12, 2024
Plasma-free Amino Acid Profile is Beneficial for Breast Cancer Screening in Women With Dense BreastsSaeko Teraoka, Hiroshi Yamamoto, Shinya Kikuchi, et al.
Breast Cancer Research : BCR|October 10, 2022
High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILsHiroko Onagi, Yoshiya Horimoto, Asumi Sakaguchi, et al.
Breast Cancer (Tokyo, Japan)|October 16, 2015
Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancerHiroko Yamashita, Akiko Ogiya, Tadahiko Shien, et al.
Human Pathology|May 28, 2026
Revisiting nuclear grade as a high-risk marker for predicting upgrade in ductal carcinoma in situYuko Ueki, Yoshiya Horimoto, Kazuharu Harada, et al.
Cell Death & Disease|May 22, 2021
IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cellsTakumi Itoh, Ryo Hatano, Yoshiya Horimoto, et al.
Breast Cancer (Tokyo, Japan)|September 16, 2016
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancerAkiko Ogiya, Kieko Yamazaki, Rie Horii, et al.
Scientific Reports|March 31, 2023
Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancerRyoko Semba, Yoshiya Horimoto, Madoka Sakata-Matsuzawa, et al.
Oncology Letters|January 25, 2019
Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancerYuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, et al.
Breast Cancer Research : BCR|July 3, 2016
Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrenceYuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
The American Journal of Pathology|July 19, 2011
ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancerYoshiya Horimoto, Johan Hartman, Julie Millour, et al.
Clinical Breast Cancer|December 12, 2024
Plasma-free Amino Acid Profile is Beneficial for Breast Cancer Screening in Women With Dense BreastsSaeko Teraoka, Hiroshi Yamamoto, Shinya Kikuchi, et al.
Breast Cancer Research : BCR|October 10, 2022
High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILsHiroko Onagi, Yoshiya Horimoto, Asumi Sakaguchi, et al.
Breast Cancer (Tokyo, Japan)|October 16, 2015
Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancerHiroko Yamashita, Akiko Ogiya, Tadahiko Shien, et al.
Human Pathology|May 28, 2026
Revisiting nuclear grade as a high-risk marker for predicting upgrade in ductal carcinoma in situYuko Ueki, Yoshiya Horimoto, Kazuharu Harada, et al.
Cell Death & Disease|May 22, 2021
IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cellsTakumi Itoh, Ryo Hatano, Yoshiya Horimoto, et al.
Breast Cancer (Tokyo, Japan)|September 16, 2016
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancerAkiko Ogiya, Kieko Yamazaki, Rie Horii, et al.
Scientific Reports|March 31, 2023
Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancerRyoko Semba, Yoshiya Horimoto, Madoka Sakata-Matsuzawa, et al.
Oncology Letters|January 25, 2019
Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancerYuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, et al.
Breast Cancer Research : BCR|July 3, 2016
Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrenceYuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, et al.
Pageof 13